497 related articles for article (PubMed ID: 27804988)
1. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
Attard G; Antonarakis ES
Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
[No Abstract] [Full Text] [Related]
2. Current understanding of resistance to abiraterone and enzalutamide in advanced prostate cancer.
Antonarakis ES
Clin Adv Hematol Oncol; 2016 May; 14(5):316-9. PubMed ID: 27379691
[No Abstract] [Full Text] [Related]
3. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
Nakazawa M; Antonarakis ES; Luo J
Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).
Penning TM
J Steroid Biochem Mol Biol; 2015 Sep; 153():105-13. PubMed ID: 26032458
[TBL] [Abstract][Full Text] [Related]
5. Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?
Antonarakis ES
Expert Rev Anticancer Ther; 2015 Feb; 15(2):143-5. PubMed ID: 25547524
[TBL] [Abstract][Full Text] [Related]
6. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.
Buttigliero C; Tucci M; Bertaglia V; Vignani F; Bironzo P; Di Maio M; Scagliotti GV
Cancer Treat Rev; 2015 Dec; 41(10):884-92. PubMed ID: 26342718
[TBL] [Abstract][Full Text] [Related]
7. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.
Liu C; Armstrong C; Zhu Y; Lou W; Gao AC
Oncotarget; 2016 May; 7(22):32210-20. PubMed ID: 27049719
[TBL] [Abstract][Full Text] [Related]
8. New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer.
Assi R; Temraz S; Shamseddine A; Mukherji D
Curr Drug Targets; 2016; 17(3):290-302. PubMed ID: 26343110
[TBL] [Abstract][Full Text] [Related]
9. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Lolli C; De Lisi D; Conteduca V; Gurioli G; Scarpi E; Schepisi G; Ravaglia G; Menna C; Farolfi A; Altavilla A; Burgio SL; Tonini G; Santini D; De Giorgi U
Prostate; 2019 Aug; 79(11):1211-1220. PubMed ID: 31251826
[TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.
De Laere B; Rajan P; Grönberg H; Dirix L; Lindberg J;
JAMA Oncol; 2019 Jul; 5(7):1060-1062. PubMed ID: 31046065
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor aberrations in the era of abiraterone and enzalutamide.
Jentzmik F; Azoitei A; Zengerling F; Damjanoski I; Cronauer MV
World J Urol; 2016 Mar; 34(3):297-303. PubMed ID: 26100946
[TBL] [Abstract][Full Text] [Related]
12. Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.
Markowski MC; Frick KD; Eshleman JR; Luo J; Antonarakis ES
Prostate; 2016 Dec; 76(16):1484-1490. PubMed ID: 27404039
[TBL] [Abstract][Full Text] [Related]
13. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
Graham L; Schweizer MT
Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
[TBL] [Abstract][Full Text] [Related]
14. Metastasis: Resistance fighters.
Savage N
Nature; 2015 Dec; 528(7582):S128-9. PubMed ID: 26672785
[No Abstract] [Full Text] [Related]
15. Persistent androgen receptor addiction in castration-resistant prostate cancer.
Schweizer MT; Yu EY
J Hematol Oncol; 2015 Nov; 8():128. PubMed ID: 26566796
[TBL] [Abstract][Full Text] [Related]
16. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J
Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164
[TBL] [Abstract][Full Text] [Related]
17. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
18. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.
Ferraldeschi R; Welti J; Luo J; Attard G; de Bono JS
Oncogene; 2015 Apr; 34(14):1745-57. PubMed ID: 24837363
[TBL] [Abstract][Full Text] [Related]
19. The evolving role of enzalutamide on the treatment of prostate cancer.
Nadal R; Bellmunt J
Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
[TBL] [Abstract][Full Text] [Related]
20. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
Del Re M; Biasco E; Crucitta S; Derosa L; Rofi E; Orlandini C; Miccoli M; Galli L; Falcone A; Jenster GW; van Schaik RH; Danesi R
Eur Urol; 2017 Apr; 71(4):680-687. PubMed ID: 27733296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
